Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Retained Earnings (2019 - 2025)

BridgeBio Pharma's Retained Earnings history spans 7 years, with the latest figure at -$3.8 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 23.41% year-over-year to -$3.8 billion; the TTM value through Dec 2025 reached -$3.8 billion, down 23.41%, while the annual FY2025 figure was -$3.8 billion, 23.41% down from the prior year.
  • Retained Earnings for Q4 2025 was -$3.8 billion at BridgeBio Pharma, down from $2000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $63000.0 in Q2 2023 and bottomed at -$3.8 billion in Q4 2025.
  • The 5-year median for Retained Earnings is -$427000.0 (2022), against an average of -$1.1 billion.
  • The largest annual shift saw Retained Earnings soared 114.75% in 2023 before it plummeted 9988045.16% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$132000.0 in 2021, then plummeted by 1453043.18% to -$1.9 billion in 2022, then skyrocketed by 100.0% to $31000.0 in 2023, then tumbled by 9988045.16% to -$3.1 billion in 2024, then decreased by 23.41% to -$3.8 billion in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Retained Earnings are -$3.8 billion (Q4 2025), $2000.0 (Q3 2025), and $1000.0 (Q2 2025).